Our Technology

The Aegis Vaccine Platform

A New Paradigm in Cross Protective Vaccines

The Aegis Vaccine Platform offers a new paradigm in cross protective vaccines. PGTx owns the exclusive global Aegis rights for viral, bacterial and parasitic diseases in humans using microbial “vectors”, including both bacteria and yeasts. Aegis utilizes recombinant technology for the insertion of bacterial, viral or protozoan genes into microbial vectors. These genes are “expressed” by the vector cell to produce specific antigens and immune enhancing proteins on the vector cell surface. Aegis vaccines use “universal” antigens which are protective across a range of pathogen strains and even species and are manufactured using a low-cost fermentation process.

How are Aegis vaccines different from traditional vaccines?

Existing “classical” vaccines mainly offer protection against specific pathogen strains used to make the vaccines. There is often little cross protection against other strains and protection against genetic changes or mutations is minimal. Aegis vaccines offer broad spectrum cross protection, reducing or eliminating the need for multiple vaccines, and they address the problem of mutation. Traditionally, inactivated vaccines are only effective as injectables, are labor intensive and costly to administer. Aegis vaccines can be delivered live or inactivated, and orally via water or spray.  


Hercules Adjuvant

A Novel Universal Adjuvant Delivery System

Hercules is a modified Chitosan adjuvant that enhances immune responses to multiple antigens, including orally administered antigens.

Hercules, when used orally promotes secretory immunoglobulin A (sIgA) on mucous membranes, inhibits pathogen invasion at the site of attack and is effective even with inactivated vaccines. Historically, orally delivered vaccines have tended to be live. Hercules is particularly useful in directing antigens toward antigen presenting cells and preliminary data indicates it acts as an effective delivery system for DNA vaccines against viral pathogens.

PGTx holds the global, exclusive rights to Hercules and it is the adjuvant for all inactivated vaccines in development based on the Aegis platform. Hercules is available for partnering and out-licensing opportunities to human vaccine companies seeking adjuvants/delivery systems for enhanced mucosal immunity and possibly oral delivery.